Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice -January 18, 2024 at 12:01 pm EST

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis in two randomized controlled Phase 3 Clinical Trials FDA Supplemental New Drug Application...

Related Keywords

,Mahboobeh Mahdavinia ,Jonathan Neely ,Rakeshk Chandra ,Jamesn Palmer ,John Messina ,Ramy Mahmoud ,Rodneyj Schlosser ,Andrewa White ,Raj Sindwani ,Zaram Patel ,Ramya Mahmoud ,Anjut Peters ,Nithind Adappa ,Grege Davis ,Zacharym Soler ,Globenewswire Inc ,Linkedin ,Exchange Commission ,Drug Administration ,Optinose Inc ,Clinical Research ,New Drug Application Filed ,Clinical Immunology ,Exhalation Delivery System ,Chronic Rhinosinusitis ,Two Randomized Controlled Trials ,Senior Vice President ,Medical Affairs ,Nasal Adverse Reactions ,Prescribing Information ,Allergy Clin ,Private Securities Litigation Reform Act ,Markets ,